KALV
KalVista Pharmaceuticals, Inc.
Key Financials
Operating Income
$-187995000
↓ 33.9%
EPS (Diluted)
$-3.69
↓ 7.3%
Total Liabilities
$7.5M
↓ 33.6%
Net Income
$-183444000
↓ 44.9%
Cash & Equivalents
$131.6M
↑ 314.0%
Shareholders' Equity
$95.4M
↓ 53.8%
Revenue
$50.0M
↑ 495.7%
Total Assets
$250.8M
↑ 6.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 6/22/2026 | View on SEC |
| EFFECT | 6/16/2026 | View on SEC |
| S-8 POS | 6/11/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| S-8 POS | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KALV |
| Company Name | KalVista Pharmaceuticals, Inc. |
| CIK | 1348911 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (857) 999-0075 |